Johnson & Johnson (JNJ) 95.11 $JNJ
J&J to Sell Sugar Substitute Splenda to Heartland Food
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 4:05PM CDT
Johnson & Johnson (JNJ) has agreed to sell its low-calorie sweetener brand, Splenda, to privately held Heartland Food Products Group.
JNJ: 95.11 (+4.38), GILD: 106.96 (+4.40), AMAG: 63.26 (+4.30), REGN: 535.47 (+36.45)
The 8th Annual Ascend National Convention, the Largest Pan-Asian Business Event of the Year, to Take Place in New York on August 29th to 31st, 2015
PRWeb - Wed Aug 26, 9:01AM CDT
Ascend, the largest non-profit Pan-Asian membership organization for business professionals in North America is celebrating its 10th Anniversary at its 8th Annual National Convention in New York City, August 29th to 31st. The Ascend Convention will be the largest gathering of Pan-Asian business leaders in North America with an expected 2,000+ registered participants.
JNJ: 95.11 (+4.38), AXS: 54.03 (+0.71), DNKN: 50.85 (+0.97), DIS: 99.23 (+3.34)
Hepatocellular Carcinoma - Pipeline Review, H1 2015
M2 - Wed Aug 26, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xkv4n3/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 100 companies featured in this report: - 4SC AG - Acceleron Pharma - Bayer - Bio-Cancer Treatment International - Caladrius Biosciences - Can-Fite BioPharma - Delcath Systems - Dicerna Pharmaceuticals - Eisai - F. Hoffmann-La Roche - Gamida Cell - Immune Network - Immunicum - Johnson & Johnson - KAHR medical - Ligand Pharmaceuticals, - Lixte Biotechnology Holdings - MaxCyte - Nerviano Medical Sciences - Nimbus Therapeutics - Omeros Corporation - Panacea Pharmaceuticals - Raptor Pharmaceuticals - Shenogen Pharma - Taiwan Liposome - VasGene Therapeutics For more information visit http://www.researchandmarkets.com/research/xk...tocellular
CANF: 1.68 (-0.04), JNJ: 95.11 (+4.38), RPTP: 12.47 (+0.59), DRNA: 10.52 (+0.44), DCTH: 0.40 (-0.04), CLBS: 1.27 (-0.01), OMER: 16.25 (-0.32), XLRN: 28.25 (+1.25)
Merus enters into 72.8 million euro series C financing led by Sofinnova Ventures and Novo A/S
PR Newswire - Wed Aug 26, 7:00AM CDT
Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with investors for the sale of up to EUR 72.8 million ($80.5 million) of Series C preferred shares and consummated the first tranche under the agreement. New investors include Sofinnova Ventures and Novo A/S as the co-leads, along with RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management and an unnamed U.S.-based life sciences-focused investor. The company's existing investors, including Novartis Venture Fund, Johnson & Johnson Innovation - JJDC, Inc., Pfizer Venture Investments, Bay City Capital, LSP Life Sciences Partners and Aglaia Oncology Fund, also participated in the financing.
JNJ: 95.11 (+4.38), NVS: 97.13 (+1.99)
'Mad Money' Lightning Round: I'm Losing Faith in Johnson & Johnson
at The Street - Wed Aug 26, 5:00AM CDT
Cramer prefers Verizon over AT&T and is staying away from Lannett Company and Zillow.
T: 32.69 (+0.89), LCI: 50.09 (+3.44), JNJ: 95.11 (+4.38), BOX: 13.25 (-0.21), IBM: 146.70 (+5.74), CNQ: 19.49 (+0.15), VZ: 45.16 (+1.66), Z: 25.00 (+0.40)
Jim Cramer's 'Mad Money' Recap: Did You Buy Big at the Open? Too Bad
at The Street - Tue Aug 25, 7:03PM CDT
Never buy stocks on big up openings, Cramer says. As proved Tuesday, what rises early often ends up falling.
VIPS: 18.63 (+0.22), CNQ: 19.49 (+0.15), BBY: 35.25 (+2.30), BWLD: 193.09 (+6.95), JNJ: 95.11 (+4.38), T: 32.69 (+0.89), W: 43.05 (+0.73), IBM: 146.70 (+5.74), CHK: 6.34 (+0.31), BHP: 34.08 (+1.16), BP: 31.10 (+0.39), CAT: 73.87 (+1.81), UNP: 84.10 (+3.54), Z: 25.00 (+0.40), GPRO: 46.28 (-0.75), NSC: 74.12 (+1.68), BOX: 13.25 (-0.21), FC: 16.87 (+0.63), COP: 43.41 (+1.22), CSX: 26.37 (+1.06), LCI: 50.09 (+3.44), GM: 28.10 (+0.82), JD: 25.59 (+0.53), CVX: 73.09 (+3.07), VZ: 45.16 (+1.66), TOL: 35.98 (+0.90), BABA: 68.66 (+0.09)
Flu vaccine breakthrough seen
at Investor's Business Daily - Tue Aug 25, 5:43PM CDT
The flu virus has stubbornly resisted attempts to create vaccines, mutating to new strains. But a team from the Scripps Research Institute (TSRI) and J&J's (JNJ) Netherlands-based Janssen Pharmaceutical unit says that it's found a way to induce...
JNJ: 95.11 (+4.38)
Johnson & Johnson (JNJ) Stock Up on Splenda Sale
at The Street - Tue Aug 25, 2:03PM CDT
Johnson & Johnson (JNJ) stock is rising after the company sold Splenda to Heartland Food Products.
JNJ: 95.11 (+4.38)
Heartland Food Products Group Enters Definitive Agreement to Acquire Splenda® Brand from Johnson & Johnson Consumer Inc.
PR Newswire - Tue Aug 25, 11:57AM CDT
Heartland Food Products Group, one of the world's leading producers and marketers of low calorie sweeteners, drink mixes, coffee, and nutritional beverages for consumer markets announced it has entered into a definitive agreement to acquire the Splenda® low calorie sweetener brand from McNeil Nutritionals, LLC, a subsidiary of Johnson & Johnson Consumer Inc. Splenda® is the leading low-calorie sweetener brand. The transaction is expected to close before the end of the year. The financial terms of the transaction have not been disclosed.
JNJ: 95.11 (+4.38)
4 Biggest Boomerang Stocks After Black Monday
at The Street - Tue Aug 25, 11:39AM CDT
The members of the Dow Jones Industrial Average that rebounded the most sharply from a Black Monday sell-off include Johnson & Johnson, Apple, United Health Group and Visa.
JNJ: 95.11 (+4.38), V: 70.69 (+3.72), UNH: 113.46 (+3.48), AAPL: 109.69 (+5.95)
7 Dividend Myths That Are Just Plain Wrong
Matthew Frankel, The Motley Fool - Motley Fool - Tue Aug 25, 5:40AM CDT
High-quality dividend stocks can be one of the best ways to create long-term wealth and minimize risk in your portfolio. Unfortunately, many investors invest in dividend stocks incorrectly (or not at all) because of some popular misconceptions. ...
T: 32.69 (+0.89), JNJ: 95.11 (+4.38)
Look for Shares of Johnson & Johnson to Potentially Rebound after Yesterday's 2.87% Sell Off
Comtex SmarTrend(R) - Mon Aug 24, 4:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $81.79 to a high of $95.21. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $95.51 on volume of 25.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 95.11 (+4.38)
Johnson & Johnson Set to Possibly Rebound After Yesterday's Selloff of 2.87%
Comtex SmarTrend(R) - Mon Aug 24, 4:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $81.79 to a high of $95.21. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $95.51 on volume of 25.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 95.11 (+4.38)
USHCC Applauds Comcast NBCUniversal for Joining the Billion Dollar Roundtable
GlobeNewswire - Mon Aug 24, 3:25PM CDT
The United States Hispanic Chamber of Commerce (USHCC) applauds Comcast NBCUniversal for being inducted into the Billion Dollar Roundtable (BDR), an organization now consisting of 21 globally-renowned corporations, created to recognize and celebrate those companies investing at least $1 billion annually with minority and women-owned suppliers. Comcast's membership in the BDR will allow it to share best practices with other like-minded corporations committed to diversity and inclusion. In addition to Comcast NBCUniversal, notable BDR member companies include AT &T, Avis Budget Group, Bank of America, Dell, Ford, Honda, IBM, Johnson & Johnson, Microsoft, Toyota and Verizon Communications.
JNJ: 95.11 (+4.38), IBM: 146.70 (+5.74)
Johnson & Johnson (JNJ) Breaks Through Support at $94.54
Comtex SmarTrend(R) - Mon Aug 24, 1:09PM CDT
Johnson & Johnson (NYSE:JNJ) has opened bearishly below the pivot of $96.53 today and has reached the first level of support at $94.54. Should the shares continue to fall, the support pivots of $93.52 and $90.51 will be of interest.
JNJ: 95.11 (+4.38)
Best in Breed: Where to Look If You Simply Must Buy Stocks Today
at The Street - Mon Aug 24, 12:00PM CDT
Limit your purchases to high-yielding industry standouts.
JNJ: 95.11 (+4.38), JPM: 62.91 (+3.00), IBM: 146.70 (+5.74), PFE: 32.43 (+1.09), KHC: 73.91 (+3.70), WMT: 64.83 (+1.73), XOM: 72.50 (+3.79), WFC: 52.30 (+2.28), BRK.B: 132.61 (+4.87), BRK.A: 200,499.92 (+6,300.00), AAPL: 109.69 (+5.95)
New Study by TSRI and Janssen Makes Major Advance Toward More Effective, Long-Lasting Flu Vaccine
PR Newswire - Mon Aug 24, 11:18AM CDT
Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes--work that could one day eliminate the need for repeated seasonal flu shots.
JNJ: 95.11 (+4.38)
These High-Quality Stocks Just Got a Whole Lot Cheaper
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 24, 11:08AM CDT
Source: Flickr user www.vpsi.org. Last week we witnessed the worst one-week stock market sell-off in four years. The Dow Jones Industrial Average shed more than 1,000 points for the week, while the broader-market S&P 500 dipped below the...
JNJ: 95.11 (+4.38), IBM: 146.70 (+5.74), AAPL: 109.69 (+5.95)
Sears Holdings Names Lynn Pendergrass As New Hardlines President
PR Newswire - Mon Aug 24, 9:00AM CDT
Sears Holdings (NASDAQ: SHLD) announced today that Lynn Pendergrass joined the company in the new role of President, Hardlines. In this position, she will be responsible for working across the Kenmore, Craftsman & DieHard business unit and its hardlines partners -- including Home Appliances, Lawn & Garden, Tools, and Sears Auto Centers -- to develop compelling offers and build relationships with members who shop the hardline categories.
JNJ: 95.11 (+4.38), SHLD: 24.00 (+0.75)
Halozyme Enzyme Could Boost Power Of Cancer Drugs
at Investor's Business Daily - Mon Aug 24, 7:02AM CDT
Halozyme Therapeutics has been one of 2015's hotter biotech stocks, but it's not exactly because of developing a drug. Halozyme's (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanze for...
JNJ: 95.11 (+4.38), HALO: 17.46 (+0.58), PFE: 32.43 (+1.09), AMGN: 153.98 (+8.79), ABBV: 63.14 (+2.43), BXLT: 35.45 (+0.72), CELG: 119.23 (+6.53)
J&J to Sell Sugar Substitute Splenda to Heartland Food
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 4:05PM CDT
Johnson & Johnson (JNJ) has agreed to sell its low-calorie sweetener brand, Splenda, to privately held Heartland Food Products Group.
JNJ: 95.11 (+4.38), GILD: 106.96 (+4.40), AMAG: 63.26 (+4.30), REGN: 535.47 (+36.45)
The 8th Annual Ascend National Convention, the Largest Pan-Asian Business Event of the Year, to Take Place in New York on August 29th to 31st, 2015
PRWeb - Wed Aug 26, 9:01AM CDT
Ascend, the largest non-profit Pan-Asian membership organization for business professionals in North America is celebrating its 10th Anniversary at its 8th Annual National Convention in New York City, August 29th to 31st. The Ascend Convention will be the largest gathering of Pan-Asian business leaders in North America with an expected 2,000+ registered participants.
JNJ: 95.11 (+4.38), AXS: 54.03 (+0.71), DNKN: 50.85 (+0.97), DIS: 99.23 (+3.34)
Hepatocellular Carcinoma - Pipeline Review, H1 2015
M2 - Wed Aug 26, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xkv4n3/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 100 companies featured in this report: - 4SC AG - Acceleron Pharma - Bayer - Bio-Cancer Treatment International - Caladrius Biosciences - Can-Fite BioPharma - Delcath Systems - Dicerna Pharmaceuticals - Eisai - F. Hoffmann-La Roche - Gamida Cell - Immune Network - Immunicum - Johnson & Johnson - KAHR medical - Ligand Pharmaceuticals, - Lixte Biotechnology Holdings - MaxCyte - Nerviano Medical Sciences - Nimbus Therapeutics - Omeros Corporation - Panacea Pharmaceuticals - Raptor Pharmaceuticals - Shenogen Pharma - Taiwan Liposome - VasGene Therapeutics For more information visit http://www.researchandmarkets.com/research/xk...tocellular
CANF: 1.68 (-0.04), JNJ: 95.11 (+4.38), RPTP: 12.47 (+0.59), DRNA: 10.52 (+0.44), DCTH: 0.40 (-0.04), CLBS: 1.27 (-0.01), OMER: 16.25 (-0.32), XLRN: 28.25 (+1.25)
Merus enters into 72.8 million euro series C financing led by Sofinnova Ventures and Novo A/S
PR Newswire - Wed Aug 26, 7:00AM CDT
Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with investors for the sale of up to EUR 72.8 million ($80.5 million) of Series C preferred shares and consummated the first tranche under the agreement. New investors include Sofinnova Ventures and Novo A/S as the co-leads, along with RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management and an unnamed U.S.-based life sciences-focused investor. The company's existing investors, including Novartis Venture Fund, Johnson & Johnson Innovation - JJDC, Inc., Pfizer Venture Investments, Bay City Capital, LSP Life Sciences Partners and Aglaia Oncology Fund, also participated in the financing.
JNJ: 95.11 (+4.38), NVS: 97.13 (+1.99)
'Mad Money' Lightning Round: I'm Losing Faith in Johnson & Johnson
at The Street - Wed Aug 26, 5:00AM CDT
Cramer prefers Verizon over AT&T and is staying away from Lannett Company and Zillow.
T: 32.69 (+0.89), LCI: 50.09 (+3.44), JNJ: 95.11 (+4.38), BOX: 13.25 (-0.21), IBM: 146.70 (+5.74), CNQ: 19.49 (+0.15), VZ: 45.16 (+1.66), Z: 25.00 (+0.40)
Jim Cramer's 'Mad Money' Recap: Did You Buy Big at the Open? Too Bad
at The Street - Tue Aug 25, 7:03PM CDT
Never buy stocks on big up openings, Cramer says. As proved Tuesday, what rises early often ends up falling.
VIPS: 18.63 (+0.22), CNQ: 19.49 (+0.15), BBY: 35.25 (+2.30), BWLD: 193.09 (+6.95), JNJ: 95.11 (+4.38), T: 32.69 (+0.89), W: 43.05 (+0.73), IBM: 146.70 (+5.74), CHK: 6.34 (+0.31), BHP: 34.08 (+1.16), BP: 31.10 (+0.39), CAT: 73.87 (+1.81), UNP: 84.10 (+3.54), Z: 25.00 (+0.40), GPRO: 46.28 (-0.75), NSC: 74.12 (+1.68), BOX: 13.25 (-0.21), FC: 16.87 (+0.63), COP: 43.41 (+1.22), CSX: 26.37 (+1.06), LCI: 50.09 (+3.44), GM: 28.10 (+0.82), JD: 25.59 (+0.53), CVX: 73.09 (+3.07), VZ: 45.16 (+1.66), TOL: 35.98 (+0.90), BABA: 68.66 (+0.09)
Flu vaccine breakthrough seen
at Investor's Business Daily - Tue Aug 25, 5:43PM CDT
The flu virus has stubbornly resisted attempts to create vaccines, mutating to new strains. But a team from the Scripps Research Institute (TSRI) and J&J's (JNJ) Netherlands-based Janssen Pharmaceutical unit says that it's found a way to induce...
JNJ: 95.11 (+4.38)
Johnson & Johnson (JNJ) Stock Up on Splenda Sale
at The Street - Tue Aug 25, 2:03PM CDT
Johnson & Johnson (JNJ) stock is rising after the company sold Splenda to Heartland Food Products.
JNJ: 95.11 (+4.38)
Heartland Food Products Group Enters Definitive Agreement to Acquire Splenda® Brand from Johnson & Johnson Consumer Inc.
PR Newswire - Tue Aug 25, 11:57AM CDT
Heartland Food Products Group, one of the world's leading producers and marketers of low calorie sweeteners, drink mixes, coffee, and nutritional beverages for consumer markets announced it has entered into a definitive agreement to acquire the Splenda® low calorie sweetener brand from McNeil Nutritionals, LLC, a subsidiary of Johnson & Johnson Consumer Inc. Splenda® is the leading low-calorie sweetener brand. The transaction is expected to close before the end of the year. The financial terms of the transaction have not been disclosed.
JNJ: 95.11 (+4.38)
4 Biggest Boomerang Stocks After Black Monday
at The Street - Tue Aug 25, 11:39AM CDT
The members of the Dow Jones Industrial Average that rebounded the most sharply from a Black Monday sell-off include Johnson & Johnson, Apple, United Health Group and Visa.
JNJ: 95.11 (+4.38), V: 70.69 (+3.72), UNH: 113.46 (+3.48), AAPL: 109.69 (+5.95)
7 Dividend Myths That Are Just Plain Wrong
Matthew Frankel, The Motley Fool - Motley Fool - Tue Aug 25, 5:40AM CDT
High-quality dividend stocks can be one of the best ways to create long-term wealth and minimize risk in your portfolio. Unfortunately, many investors invest in dividend stocks incorrectly (or not at all) because of some popular misconceptions. ...
T: 32.69 (+0.89), JNJ: 95.11 (+4.38)
Look for Shares of Johnson & Johnson to Potentially Rebound after Yesterday's 2.87% Sell Off
Comtex SmarTrend(R) - Mon Aug 24, 4:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $81.79 to a high of $95.21. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $95.51 on volume of 25.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 95.11 (+4.38)
Johnson & Johnson Set to Possibly Rebound After Yesterday's Selloff of 2.87%
Comtex SmarTrend(R) - Mon Aug 24, 4:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $81.79 to a high of $95.21. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $95.51 on volume of 25.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 95.11 (+4.38)
USHCC Applauds Comcast NBCUniversal for Joining the Billion Dollar Roundtable
GlobeNewswire - Mon Aug 24, 3:25PM CDT
The United States Hispanic Chamber of Commerce (USHCC) applauds Comcast NBCUniversal for being inducted into the Billion Dollar Roundtable (BDR), an organization now consisting of 21 globally-renowned corporations, created to recognize and celebrate those companies investing at least $1 billion annually with minority and women-owned suppliers. Comcast's membership in the BDR will allow it to share best practices with other like-minded corporations committed to diversity and inclusion. In addition to Comcast NBCUniversal, notable BDR member companies include AT &T, Avis Budget Group, Bank of America, Dell, Ford, Honda, IBM, Johnson & Johnson, Microsoft, Toyota and Verizon Communications.
JNJ: 95.11 (+4.38), IBM: 146.70 (+5.74)
Johnson & Johnson (JNJ) Breaks Through Support at $94.54
Comtex SmarTrend(R) - Mon Aug 24, 1:09PM CDT
Johnson & Johnson (NYSE:JNJ) has opened bearishly below the pivot of $96.53 today and has reached the first level of support at $94.54. Should the shares continue to fall, the support pivots of $93.52 and $90.51 will be of interest.
JNJ: 95.11 (+4.38)
Best in Breed: Where to Look If You Simply Must Buy Stocks Today
at The Street - Mon Aug 24, 12:00PM CDT
Limit your purchases to high-yielding industry standouts.
JNJ: 95.11 (+4.38), JPM: 62.91 (+3.00), IBM: 146.70 (+5.74), PFE: 32.43 (+1.09), KHC: 73.91 (+3.70), WMT: 64.83 (+1.73), XOM: 72.50 (+3.79), WFC: 52.30 (+2.28), BRK.B: 132.61 (+4.87), BRK.A: 200,499.92 (+6,300.00), AAPL: 109.69 (+5.95)
New Study by TSRI and Janssen Makes Major Advance Toward More Effective, Long-Lasting Flu Vaccine
PR Newswire - Mon Aug 24, 11:18AM CDT
Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes--work that could one day eliminate the need for repeated seasonal flu shots.
JNJ: 95.11 (+4.38)
These High-Quality Stocks Just Got a Whole Lot Cheaper
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 24, 11:08AM CDT
Source: Flickr user www.vpsi.org. Last week we witnessed the worst one-week stock market sell-off in four years. The Dow Jones Industrial Average shed more than 1,000 points for the week, while the broader-market S&P 500 dipped below the...
JNJ: 95.11 (+4.38), IBM: 146.70 (+5.74), AAPL: 109.69 (+5.95)
Sears Holdings Names Lynn Pendergrass As New Hardlines President
PR Newswire - Mon Aug 24, 9:00AM CDT
Sears Holdings (NASDAQ: SHLD) announced today that Lynn Pendergrass joined the company in the new role of President, Hardlines. In this position, she will be responsible for working across the Kenmore, Craftsman & DieHard business unit and its hardlines partners -- including Home Appliances, Lawn & Garden, Tools, and Sears Auto Centers -- to develop compelling offers and build relationships with members who shop the hardline categories.
JNJ: 95.11 (+4.38), SHLD: 24.00 (+0.75)
Halozyme Enzyme Could Boost Power Of Cancer Drugs
at Investor's Business Daily - Mon Aug 24, 7:02AM CDT
Halozyme Therapeutics has been one of 2015's hotter biotech stocks, but it's not exactly because of developing a drug. Halozyme's (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanze for...
JNJ: 95.11 (+4.38), HALO: 17.46 (+0.58), PFE: 32.43 (+1.09), AMGN: 153.98 (+8.79), ABBV: 63.14 (+2.43), BXLT: 35.45 (+0.72), CELG: 119.23 (+6.53)
